Dr. Skaff’s academic background was primarily focused on the structure/function relationship of metabolic proteins and has provided a foundation for achieving a deeper understanding of biological processes with the goal of discovering solutions for human diseases and control or prevention of microbial infections. Andrew received a Ph.D. in Biochemistry from Iowa State University studying human brain hexokinase and its release from the mitochondrial membrane. With his background in enzyme kinetics, he shifted to large scale screening of compound libraries in search of lead compounds for inhibition of the cholesterol synthesis pathway, which has applications as an alternative to the statin-class of drugs as well as antimicrobial effects. He then applied the understanding of these physical techniques to computationally screening millions of compounds to aid in more rapidly identifying lead compounds at a significantly lower cost. As the Principal Scientist at Zorilla Research, Andrew led a number of computational drug discovery projects with both corporate and academic partnerships. Andrew is currently the Chief Science Officer and Chief Operations Officer of Eir Pharmaceuticals, LLC, a Kansas City-based biotech startup, dedicated to developing therapeutic consumer goods and pharmaceuticals.